Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Read-Gene

2005 FOUNDED
PUBLIC STATUS
21-30 EMPLOYEES
RDG STOCK SYMBOL
$0.27 SHARE PRICE (As of Friday Closing)
Description

Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Stock Exchange
WAR
Primary Office
  • Ul. Alabastrowa 8
  • Grzepnica, 72-003
  • Poland

+48 91 000 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Read-Gene’s full profile, request a free trial.

Read-Gene Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.15 - $0.27 $3.24M $0.26 883.33 11.8M

Read-Gene Financials Summary

In Thousands,
USD
TTM
30-Sep-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 2,996 4,455 3,423 3,474
Revenue 966 1,270 1,318 429
EBITDA (122) 53 (36) 292
Net Income (150) 14 (125) (180)
Total Assets 4,465 5,226 4,288 3,629
Total Debt 0 0 0 189
Public Fundamental Data provided by Morningstar, Inc. disclaimer